Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 06, 2022 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) -- -- EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue Interest...
September 01, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present at Investor Conferences in September

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
August 08, 2022 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
August 03, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
August 02, 2022 07:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update

-- Received FDA approval for IMCIVREE® (setmelanotide) as the first-ever therapy for patients with Bardet-Biedl syndrome -- -- U.S. launch off to a strong start with more than 50 IMCIVREE...
July 28, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022

BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
July 22, 2022 08:39 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼¹ IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

-- European Commission decision anticipated in fourth quarter of 2022 -- BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical...
July 20, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

BOSTON, July 20, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
July 20, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

-- Reimbursed early access program allows for patients in France to receive setmelanotide for treatment of obesity and control of hunger associated with BBS -- BOSTON, July 20, 2022 (GLOBE...
July 18, 2022 06:00 ET | Source: Rhythm Pharmaceuticals, Inc.

NICE Recommends Rhythm’s ▼IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

- IMCIVREE will be funded and available for use within 90 days in the National Health Service - BOSTON, July 18, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a...